Valeant Pharmaceuticals: Aggressive Accounting Games

By Maureen McNichols, Jaclyn Foroughi
2017 | Case No. A229 | Length 33 pgs.
In February 2008, as world markets slid deeper into economic decline, J. Michael Pearson joined Valeant Pharmaceuticals, a specialty pharmaceuticals company, then based in a quiet suburb of southern California. By August 2015, the stock price peaked, valuing the company at nearly $90 billion, up from $2 billion in 2008. In that time, Valeant had made over 100 acquisitions with total revenues growing from roughly $750 million in 2008 to over $10 billion in 2015. The explosive growth of Valeant in just seven-and-a-half years was not without purpose.
This material is available for download by current Stanford GSB students, faculty, and staff only. For inquires, contact the Case Writing Officeopen in new window. Download